BreathDx – molecular analysis of exhaled breath as a diagnostic test for ventilator–associated pneumonia: protocol for a European multicentre observational study
Authors:
- on behalf of the BreathDx ConsortiumOCon behalf of the BreathDx Consortium
- Pouline M. P. van OortPOPouline M. P. van Oort
- Paul DarkPDPaul Dark
- Oluwasola LawalOLOluwasola Lawal
Open Access
- 3 January 2017
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 17 (1) , 1-8
Abstract
The diagnosis of ventilator-associated pneumonia (VAP) remains time-consuming and costly, the clinical tools lack specificity and a bedside test to exclude infection in suspected patients is unavailable. Breath contains hundreds to thousands of volatile organic compounds (VOCs) that result from host and microbial metabolism as well as the environment. The present study aims to use breath VOC analysis to develop a model that can discriminate between patients who have positive cultures and who have negative cultures with a high sensitivity. The Molecular Analysis of Exhaled Breath as Diagnostic Test for Ventilator-Associated Pneumonia (BreathDx) study is a multicentre observational study. Breath and bronchial lavage samples will be collected from 100 and 53 intubated and ventilated patients suspected of VAP. Breath will be analysed using Thermal Desorption – Gas Chromatography – Mass Spectrometry (TD-GC-MS). The primary endpoint is the accuracy of cross-validated prediction for positive respiratory cultures in patients that are suspected of VAP, with a sensitivity of at least 99% (high negative predictive value). To our knowledge, BreathDx is the first study powered to investigate whether molecular analysis of breath can be used to classify suspected VAP patients with and without positive microbiological cultures with 99% sensitivity. UKCRN ID number 19086, registered May 2015; as well as registration at www.trialregister.nl under the acronym ‘BreathDx’ with trial ID number NTR 6114 (retrospectively registered on 28 October 2016).Keywords
Funding Information
- European Commission (BE) (611951)
This publication has 47 references indexed in Scilit:
- Exhaled molecular profiles in the assessment of cystic fibrosis and primary ciliary dyskinesiaJournal of Cystic Fibrosis, 2013
- Volatile Metabolites of Pathogens: A Systematic ReviewPLOS Pathogens, 2013
- Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic reviewRespiratory Research, 2012
- Biomarkers for ventilator-associated pneumonia: Review of the literatureHeart & Lung, 2011
- Sparse Partial Least Squares Regression for Simultaneous Dimension Reduction and Variable SelectionJournal of the Royal Statistical Society Series B: Statistical Methodology, 2010
- Diagnostic importance of pulmonary interleukin-1 and interleukin-8 in ventilator-associated pneumoniaThorax, 2009
- Highly sensitive feature detection for high resolution LC/MSBMC Bioinformatics, 2008
- Ventilator-Associated Pneumonia: Diagnosis, Treatment, and PreventionClinical Microbiology Reviews, 2006
- XCMS: Processing Mass Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and IdentificationAnalytical Chemistry, 2006
- Matched filtering with background suppression for improved quality of base peak chromatograms and mass spectra in liquid chromatography–mass spectrometryAnalytica Chimica Acta, 2002